NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Contact the NSABP   Pathology Section   Future Meetings   NSABP Newsletters   Media Info on cMYC Study   Media Info on STAR   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-37   Protocol B-39   Protocol B-40   Protocol B-41   Protocol B-42   Protocol B-43   Protocol BP-59   Protocol R-04 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR   BreastCancerPrevention.com Bibliography of Publications Related Web Sites About the NSABP Web Site Medical Search Engines To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview Protocol B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer Specific Aim To determine whether or not prolonged adjuvant hormonal therapy with letrozole will improve disease-free survival in postmenopausal women with ER-positive and/or PgR-positive tumors who have completed 5 years of hormonal therapy with 5 years of an aromatase inhibitor (AI) or 5 years of a combination of up to 3 years of tamoxifen followed by an AI.